Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Antimicrob Chemother ; 74(10): 2913-2915, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31340021

ABSTRACT

BACKGROUND: The emergence of drug-resistant Neisseria gonorrhoeae has prompted the development of rapid molecular assays designed to determine antimicrobial susceptibility. One common assay uses high-resolution melt analysis to target codon 91 of the gyrase A gene (gyrA) to predict N. gonorrhoeae susceptibility to ciprofloxacin. METHODS: We extracted DNA from remnant clinical specimens that had previously tested positive for N. gonorrhoeae using the Aptima Combo 2 for CT/NG assay (Hologic, San Diego, CA, USA). We selected DNA extracts from specimens with indeterminate, WT and mutant gyrA genotype results from a previous study using high-resolution melt analysis to detect the gyrA codon 91 mutation. We re-tested those specimens using the recently CE-marked ResistancePlus GC (beta) assay (SpeeDx, Sydney, Australia). RESULTS: Of 86 specimens with indeterminate gyrA genotypes on high-resolution melt analysis, the ResistancePlus GC (beta) assay (SpeeDx) identified 30 (35%) WT, 22 (26%) mutant and 34 (40%) indeterminate gyrA genotypes. CONCLUSIONS: The ResistancePlus GC (beta) assay showed improved N. gonorrhoeae gyrA genotype determination compared with a prior gyrA genotypic high-resolution melt assay.


Subject(s)
Anti-Bacterial Agents/pharmacology , Ciprofloxacin/pharmacology , DNA Gyrase/genetics , Genotyping Techniques/methods , Microbial Sensitivity Tests/methods , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/enzymology , Drug Resistance, Bacterial , Genotype , Gonorrhea/microbiology , Humans , Neisseria gonorrhoeae/genetics , Neisseria gonorrhoeae/isolation & purification , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...